Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
Confidential
A new class of drugs to modulate
THE HUMAN MICROBIOME
Jonathan Freeman
CBO
Jefferies Healthcare Conference
NYC 06-07-2017
CONFIDENTIAL
Important Information1
The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question
and answer session and any document or material distributed at or in connection with the presentation (together, the "Presentation"), has been prepared by PureTech Health plc (the "Company"). The
information in the Presentation is not intended to form the basis of any contract. By attending (whether in person or by telephone) or reading the Presentation, you agree to the conditions set out below.
THIS DOCUMENT AND THE PRESENTATION IS NOT A PROSPECTUS. The Presentation does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe
for, any shares or other securities of the Company, nor shall it (or any part of it), or the fact of its distribution, form the basis of, or be relied on in connection with or act as any inducement to enter into, any
contract whatsoever relating to any securities.
This document and the Presentation contain statements that are or may be forward-looking statements. These statements are based on our management’s current beliefs, expectations and
assumptions about future events, conditions and results, and on information currently available to us. This document and the Presentation also contain estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give
undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.
All statements other than statements of historical facts included in this document may be forward-looking statements, including statements that relate to the Company's future prospects,
developments and strategies. Words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,” “think,” “may,” “could,” “will,” “would,” “should,” “continue,” “potential,” “likely,” “opportunity” and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking
statements. Additionally, statements concerning future matters such as our expectations of business and market conditions, development and commercialization of new products, enhancements of existing products or technologies, and other statements regarding matters that are not historical are forward-looking statements. Such statements are based on currently available operating,
financial and competitive information and are subject to various risks, uncertainties and assumptions that could cause actual results to differ materially from those anticipated or implied in our forward-looking statements due to a number of factors including, but not limited to:
The Company’s business is subject to a number of risks and uncertainties. These risks are described in the Company’s 2016 Annual Report and Accounts which can found on the Company’s web
site at http://puretechhealth.com/investors-reports-presentations.php.
Given these risks, uncertainties and other factors, many of which are beyond our control, you should not place undue reliance on these forward-looking statements.
Each forward-looking statement speaks only as at the date of this document. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to revise
any forward-looking statements to reflect events or developments occurring after the date of this document, even if new information becomes available in the future.
The Presentation is confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed by its recipients to any other person for any purpose, other than with the consent of the Company. The Presentation does not constitute or form part of an offer or invitation to issue or sell, or the solicitation of an offer to subscribe or purchase, any securities to any person.
By accepting receipt of, attending any delivery of, or electronically accessing, the Presentation, you agree to be bound by the above limitations and conditions and, in particular, you represent, warrant and undertake to the Company that: (i) you will not forward the Presentation to any other person, or reproduce or publish this document, in whole or in part, for any purpose and (ii) you
have read and agree to comply with the contents of this notice.
1: Vedanta Biosciences is a subsidiary of PureTech Health
CONFIDENTIAL
Medicine meets Ecology
3
CONFIDENTIAL
What Makes Vedanta Unique?
Careful science, independently reproduced, peer reviewed
in seminal papers (Nature, Science, Cell)
World leading scientific founders in immunology/microbiome
Top Science in
Microbiome Field
Key IP for development of bacterial consortia drugs
Issued composition of matter claims covering key
highly abundant gut bacteria
Earliest priority dates among microbiome companies
Applying pharma rigor to rationally select defined drugs
based on consortia of live commensal bacteria
Safer, more scalable, reproducible than fecal transplants
Validated discovery & GMP manufacturing platform for
defined bacterial drugs
Sole focus on
Rationally-Defined
Live Bacterial Drugs
4
Foundational
Microbiome IP
CONFIDENTIAL 5
Pioneering Microbiome-Derived Immunotherapies Relevant to Immune-driven and Infectious Disease
CONFIDENTIAL
Co-Founders and Scientific AdvisorsMicrobiome and Immunology Pioneers
Discovered role of Toll–Like Receptors in
immunity
First to clone CD4 Co-Receptor, Pioneered
understanding of Th17 cellsDan Littman
Alexander Rudensky Pioneered under-standing of regulatory T cells
(Treg) & discovered role of Foxp3
Brett FinlayPioneer of host-microbe interactions &
mechanisms of infection
Kenya HondaPioneer of host-microbe interactions, discovered
role of microbiota in immunoregulation
6
Ruslan Medzhitov
Jeremiah Faith Leader in development of experimental and
computational tools to study the microbiota
CONFIDENTIAL
Rationally Defined Bacterial Consortia?Ecology-Level Interventions Designed with Pharmaceutical Rigor
7
Fecal Transplant Procedures
Defined Bacterial Consortia Drugs
Single Strains orSmall Molecules
Overly reductionistic,
fails at shifting ecosystem
Can shift ecosystem,
untargeted, variable procedure
Shifts ecosystem with
targeted immune responses
CONFIDENTIAL
Rationally Defined Bacterial ConsortiaEcology-Level Interventions Designed with Pharmaceutical Rigor
8
Single Strains
Imm
unolo
gic
al eff
ect
e.g
. Fo
xp3 +
CD
4
Single strains don’t reproducibly shift
microbiome, weak immune modulation
Rationally defined consortia capable of
shifting microbiome, robust immune response
CONFIDENTIAL
Rationally-Designed Bacterial Consortia Examples of Commensal Consortia Effective in Pre-clinical models
9
C. difficile Infection
Negative control
Positive control
Consortium
Sur
viva
l
Time
IL10-/- (colitis)
Sco
ring
Graft vs Host Disease
+LBP+LBP)
Sur
viva
l
Time
Negative control
Induced Food Allergy
+LBP
Sco
ring
Control
Consortium
Induction schedule
Consortium
CONFIDENTIAL 10
Foundational Intellectual Property Covering Large & Immunologically-Influential Microbiota Clusters
• DOMINANT PATENT POSITION TO OPERATE IN DEVELOPMENT OF BACTERIAL CONSORTIA DRUGS
• 12 ALLOWED PATENTS (US, EU, JP) BROADLY COVERING COMPOSITIONS OF MATTER, 2010 PRIORITY DATES
Clostridia Clusters IV and XIVa:
One of the Largest Clusters in the Microbiota
VE202
VE303
OthersFirmicutesBacteroidetes
Actinobacteria
Other
Total Microbiota Clostridia
Clusters IV and XIVa
CONFIDENTIAL
Platform for Sustainable Value CreationState-of-the-Art Capabilities and Assets in Microbiome Field
11
CONFIDENTIAL
Broad Translational Medicine-backed PipelineTargeting Patient Needs in Immune-driven and Infectious Disease
12
VE404 Food Allergy
VE606 MDROs and Graft-vs-Host Disease
VE808 Cancer Immunotherapy, Several Indications
DISCOVERY PRECLINICAL CLINICAL
VE303 C. difficile
VE202 Colitis & Crohn’s
GMP MANUF.
Aug 2016 — Analyzing gut microbiome patterns in melanoma, lung cancer, and bladder cancer patients associated with response, and developing microbiome-derived immunotherapies
Jan 2015 —licensing agreement for development of VE202 in IBD, with up-front and milestone payments of up to $339M plus royalties
Feb 2017 — Analyzing changes in the gut microbiome that may explain clinical response to oral immunotherapies in children with peanut allergies
Feb 2017 — generating clinical data from microbiome interventional studies in C. difficile patients
Feb 2017 — generating clinical data from microbiome interventional and observational studies in graft-versus-host disease
CONFIDENTIAL
Chris ViehbacherChairman of Board of Directors; Former CEO
and Member of the Board of Directors, Sanofi
Ben ShapiroFormer Exec VP of Research, Merck; led
research programs for 25 FDA approvals of
drugs & vaccines
John LaMattinaFormer President of Global R&D, Pfizer; led
approval of numerous new drugs, including:
Tarceva, Chantix, Zoloft, Selzentry, Lyrica
Board of Directors
Management Team
Dan CoutoSVP, Head of Manufacturing & Operations;
Former SVP Manufacturing & Operations
ContraFect, Merck
Jonathan FreemanChief Business Officer Former SVP, Head
of Strategy Development and Portfolio
Management, Merck KGaA
Deb WinslowVP, Program Management & Operations
Former VP Project Management & QA
GTC Biotherapeutics, Ra pharma
13
Bernat OlleChief Executive Officer, Co-Founder;
MIT TR35 Spain Innovator of the Year,
MIT PhD in bacterial fermentation & MBA
Bruce RobertsChief Scientific Officer
Former Head MS & Autoimmunity, Sanofi
Genzyme; 9 approvals, including aubagio
Leadership Team Extensive Industry Experience
David SteinbergCo-Founder, Director;
Executive VP, PureTech Health
Erik SpekHead of IP
Former Director of IP, Epizyme;
Wolf & Greenfield
CONFIDENTIAL
SummaryPioneering Microbiome-Derived Immunotherapies
Addressing Multiple Therapeutic Indications in
Immune & Infectious DiseaseBroad Pipeline
Leading Therapeutics Company Pioneering Rational
Drug Development in Microbiome FieldTransformative Science
Issued Product Claims Covering Key Bacteria,
Encompassing 30-50% of Gut Microbiota
Foundational
Microbiome IP
Discovery and GMP Manufacturing Platform for Well-
Defined Live Bio-Therapeutic Products
Platform for
Well-Defined Drugs
Multiple Seminal Publications in Top-Tier Journals &
pharma partnershipExternal Validation
14